文献速递鼻科

既往内镜鼻窦手术范围对CRSwNP患者度普利尤单抗疗效的影响

Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients.
PubMed 文献 · Laryngoscope · 2023-08-26

这项多中心回顾性研究纳入145例既往接受过至少一次内镜鼻窦手术的慢性鼻窦炎伴鼻息肉(CRSwNP)患者,以ACCESS评分评估手术范围,分析其与度普利尤单抗治疗结局的关联。结果显示较低ACCESS评分(更广泛手术)与各时间点更好的鼻息肉评分及30天SNOT-22、鼻塞和流涕VAS相关,但嗅觉丧失VAS显著更差。

要点

  • 既往内镜鼻窦手术更广泛(低ACCESS评分)者,度普利尤单抗治疗后鼻息肉评分及部分主观症状更优。
  • 手术范围更广泛者嗅觉恢复机会可能降低,嗅觉丧失VAS显著更差。
  • 研究为多中心回顾性设计,证据等级3。

核心结论

  • 与接受最小范围切除的患者相比,既往接受广泛内镜鼻窦手术的度普利尤单抗治疗患者可能鼻息肉体积更小、主观指标改善,但嗅觉恢复机会降低。

研究设计与样本

  • 多中心回顾性研究,纳入145例接受度普利尤单抗治疗且启动前至少接受过一次内镜鼻窦手术的CRSwNP患者。
  • 根据启动度普利尤单抗前的CT扫描为每例患者分配ACCESS评分。
  • 收集治疗前及治疗期间的主观和客观参数(SNOT-22、NPS、VAS评分、Sniffin' Sticks)。
  • 分析ACCESS评分与临床结局之间的统计学相关性。

主要发现

  • 距末次内镜鼻窦手术的平均时间为68.6个月,患者平均接受2.2次手术。
  • 低ACCESS评分(更广泛内镜鼻窦手术)患者在所有时间点鼻息肉评分(NPS)更优。
  • 低ACCESS评分患者30天SNOT-22、鼻塞VAS和流涕VAS更优。
  • 低ACCESS评分患者嗅觉丧失VAS值显著更差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend that the vast majority of patients with severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) should have at least one endoscopic sinus surgery (ESS) prior to starting biologics. Because ESS can be performed with a variable extension, the aim of this study would be to evaluate the association between surgical extensiveness, as measured by ACCESS score, and outcomes collected in patients treated with Dupilumab. MATERIALS AND METHODS: This is a multicentric retrospective study; patients affected by CRSwNP who were subjected to Dupilumab therapy and who underwent at least one ESS prior to Dupilumab initiation were included. ACCESS score was assigned to each patient's pre-Dupilumab CT scan. Subjective and objective parameters (SNOT-22, NPS, VAS scores, Sniffin' Sticks) were collected before and during the administration of therapy. Statistical correlations between ACCESS scores and clinical outcomes were investigated. RESULTS: A total of 145 patients were included; mean time from last previous ESS was 68.6 months, and on average, patients were subjected to 2.2 surgeries. Many correlations with ACCESS scores were demonstrated: better NPS at all timepoints and subjective scores (30-days SNOT-22, VAS nasal obstruction, and rhinorrhea) were achieved in patients with low ACCESS score (more extensive ESS). On the other hand, significantly worse VAS loss of smell values were demonstrated in patients with lower ACCESS scores. CONCLUSION: Dupilumab patients subjected to a prior extensive ESS may have reduced size of polyps and improved subjective indicators, together with a decreased chance to recover smell, when compared with patients who underwent a minimal excision. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:1556-1563, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Alicandri-Ciufelli M, Marchioni D, Pipolo C, et al. Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients. Laryngoscope. 2023. PMID: 37632705. doi:10.1002/lary.30983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。